Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
DXE2GK
|
||||
| Drug Name |
N-(4-tert-butylphenyl)-5-(1-methyl-4-(pyridin-4-ylmethylamino)-1H-imidazol-5-yl)-1,3,4-oxadiazol-2-amine
|
||||
| Synonyms |
CHEMBL203731
|
||||
| Indication | Discovery agent | Investigative | [1587926] | ||
| Formula |
C22H25N7O
|
||||
| Canonical SMILES |
Cn1cnc(NCc2ccncc2)c1c3oc(Nc4ccc(cc4)C(C)(C)C)nn3
|
||||
| InChI |
InChI=1S/C22H25N7O/c1-22(2,3)16-5-7-17(8-6-16)26-21-28-27-20(30-21)18-19(25-14-29(18)4)24-13-15-9-11-23-12-10-15/h5-12,14,24H,13H2,1-4H3,(H,26,28)
|
||||
| InChIKey |
DXPJRFUAXOWMTL-UHFFFAOYSA-N
|
||||
| Target and Pathway | |||||
| Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | [1587926] | ||
| Vascular endothelial growth factor receptor 1 | Target Info | [1587926] | |||
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| VEGF signaling pathway | |||||
| Focal adhesion | |||||
| Proteoglycans in cancerhsa04014:Ras signaling pathway | |||||
| HIF-1 signaling pathway | |||||
| Transcriptional misregulation in cancer | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| VEGF signaling pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| Beta3 integrin cell surface interactions | |||||
| Signaling events mediated by TCPTP | |||||
| SHP2 signaling | |||||
| S1P1 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| Integrins in angiogenesis | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Notch-mediated HES/HEY networkglypican_1pathway:Glypican 1 network | |||||
| S1P3 pathway | |||||
| VEGFR1 specific signals | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.